Q-omics provides the consensus-scored CPXCR1 profile across patient tissues and cancer cell-line models. CPXCR1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CPXCR1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, CPXCR1 RNA expression shows 6,423 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where CPXCR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPXCR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPXCR1 survival associations across molecular data types. CPXCR1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPXCR1 RNA expression–survival associations across cancer types. High CPXCR1 expression shows unfavorable associations in KIRC, THYM, BLCA, MESO and OV, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CPXCR1 RNA expression.
This table summarizes CPXCR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CPXCR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPXCR1 shows lower tumor expression in LUSC and higher tumor expression in HNSC, THCA and LIHC. The HNSC box plot shows higher CPXCR1 RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p < 0.001).
This table shows molecular features associated with CPXCR1 in patient tissues and cancer cell lines. In patient samples, CPXCR1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CPXCR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
